Boston Scientific agrees to acquire Relievant Medsystems
Summary
Boston Scientific has entered into a definitive agreement to acquire Relievant Medsystems, a privately held medical technology company that has developed and commercialised the Intracept Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The therapy uses targeted radiofrequency energy to stop the basivertebral nerve from transmitting pain signals to the brain and is designed to improve function and provide long-term relief. Jim Cassidy, president, neuromodulation, Boston Scientific, said: ″We anticipate this novel, clinically backed technology can support our category leadership strategy while expanding access to care for individuals who need personalised treatment. On a GAAP basis, the transaction is expected to be more dilutive due to amortisation expense and acquisition-related charges. Together with Boston Scientific, we can accelerate our journey to provide life-changing relief to patients by transforming the diagnosis and treatment of vertebrogenic pain.”